Clinical reference Biomarker Directory
Back to directory

C7

Established

C7 is a terminal complement/MAC component; deficiency causes selective Neisseria infection susceptibility.

Also known as Complement component 7
In plain language

C7 is part of the same "kill switch" complex as C5 and C6. Its absence causes the same pattern: a specific vulnerability to Neisseria bacteria, which is why testing the whole terminal complement group together makes sense when this is suspected.

Biomarker & context

C7 is another membrane attack complex component of the terminal complement pathway, working alongside C5, C6, C8, and C9 to form the pore that lyses target bacterial cells.

What it indicates

C7 deficiency follows the same terminal complement pattern: increased susceptibility to disseminated Neisseria infections (meningitis, gonococcal infection), without the broader infection risk or autoimmune association seen in earlier complement component deficiencies.

Diagnosis & clinical testing

Identified through abnormal CH50/AH50 screening followed by individual terminal complement component testing; often diagnosed after a patient presents with recurrent or unusually severe meningococcal disease.

Guiding treatment

As with other terminal deficiencies, meningococcal vaccination and prompt treatment of any Neisseria infection are the mainstays of management once identified.

Clinical significance

Part of the shared C5-C9 terminal pathway deficiency syndrome.

References
  1. StatPearls. (2023). Complement Deficiency.